For hospitals, health systems, and imaging centers
Fill your screening program. Read every scan with a second opinion.
Most patients eligible for lung cancer screening are already in your records or at a community health center nearby. Oatmeal Health finds them, reaches them, and gives your radiologists an AI second opinion on every low-dose CT.
Sources: American Lung Association, State of Lung Cancer 2022. Bandi et al., JAMA, November 2025. Oatmeal Health FQHC network.
Find them, reach them, read their scans.
Eligible patients are already in your records and at community health centers near you. Oatmeal Health finds them, reaches them, and gives your radiologists a second opinion on every scan.
AI analyzes your patient records to surface everyone who meets USPSTF lung cancer screening criteria.
- Works from a CSV or flat file export
- 9x more efficient than manual chart review
- 94% precision on top-ranked patients
- Runs on your servers or our HIPAA-compliant cloud
An AI patient scheduler texts first, then calls in 70+ languages, prepares patients for their shared decision-making visit, and hands them to your team.
- Heads-up text before every call
- Identifies itself as automated
- Hands off to a real person with a call summary
- Runs within the calling hours you set
LungAI gives your radiologists a 0 to 100 malignancy score for each nodule, inside the CADe or PACS viewer they already use. LungAI is investigational and not FDA 510(k) cleared.
- CADx malignancy scoring inside partner CADe and PACS viewers
- Prior-scan comparison built in
- PDF report delivered to PACS
- Compatible with GE, Philips, and Siemens scanners
Earlier detection saves lives
Every stage shift from IV to I saves a life and cuts treatment costs by 4 to 6x. Oatmeal Health is built to help find cancers while they are still surgical.
| Stage | Five year survival | Est. treatment cost | What This Means |
|---|---|---|---|
| Stage I | 70 to 90% | ~$200K | Surgery + monitoring. Best outcome. Our target. |
| Stage II | 50 to 60% | ~$310K | More aggressive treatment. Chemo likely. |
| Stage III | 20 to 40% | ~$480K | Radiation + chemo + possible surgery. |
| Stage IV | About 10% | ~$800K to $1.2M | Palliative focus. Immunotherapy. |
Estimates. For a system treating 100 lung cancer cases, shifting detection from Stage IV to Stage I saves an estimated $60M to $100M in treatment costs. Stage IV costs include immunotherapy such as Keytruda, which alone lists at about $217,000 per year ($12,517 per dose every 3 weeks, Merck list price, 2026). Cost source: McGarvey et al., BMC Health Services Research, 2022. Five year survival ranges are approximate by stage at diagnosis.
The consortium model: scan volume from community health centers
FQHCs identify screening-eligible patients through LungIQ but lack CT scanners. Oatmeal Health connects your imaging center with community health centers in your region who are actively identifying and referring eligible patients. You get referred scan volume. FQHCs get a downstream pathway.
"Our collaboration with Oatmeal Health extends beyond technology partnerships to secure insurance reimbursement-based revenue structures for actual US patients and establish leading technology in the lung cancer screening market."
Ready to grow your screening program?
Whether you want to see it in your CADe viewer or build a full lung screening program, the next step takes less than 30 minutes.
See LungAI in your workflow
A live demo showing how LungAI appears inside your CADe viewer, what the score looks like per nodule, and how the PDF report is delivered into PACS.
Request a Workflow DemoBuild a lung screening program
How Oatmeal Health drives scan referrals to your center through the consortium model and integrates LungAI into your CADe workflow.
Talk to Our TeamLungAI is investigational and not FDA cleared.